Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 18/20 | 0.61 |
| ▸ | PTPN5 | P54829 | 18/20 | 0.61 |
| ▸ | PTPN2 | P17706 | 17/20 | 0.61 |
| ▸ | HSPD1 | P10809 | 5/20 | 0.61 |
| ▸ | HSPE1 | P61604 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085283 | 0.92 | PTPN1 (0.61) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6084199 | 0.92 | PTPN2 (0.54) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6086234 | 0.90 | PTPN5 (0.74) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6085204 | 0.87 | PTPN1 (0.61) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6084264 | 0.83 | PTPN2 (0.66) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6202869 | 0.81 | MAPT (0.58) | PTPN1PTPN5PTPN2MEN1LMNA | |
| SCHEMBL6086345 | 0.81 | MAPT (0.54) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6200297 | 0.81 | PTPN1 (0.63) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6085198 | 0.81 | PTPN1 (0.61) | PTPN1PTPN5PTPN2HSPD1HSPE1 | |
| SCHEMBL6086151 | 0.80 | PTPN2 (0.63) | PTPN1PTPN5PTPN2HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | disclosed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | disclosed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | MAP3K15, MAP3K20, MAP3K3 | PTPN1 344/4885PTPN5 362/4885PTPN2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.